ImmunityBio Stock Rises on FDA Acceptance for Anktiva Label Expansion
Shares of ImmunityBio (NASDAQ: IBRX) rose over 9% after the company announced that its supplemental biologics license application for Anktiva was accepted by the FDA. The approval could expand Anktiva's use to treat a larger patient population with bladder cancer, potentially increasing market demand and insurer coverage.
Tickers: $IBRX